Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome + Capecitabine in Recurrent Metastatic Nasopharyngeal Carcinoma
NCT05717764Phase 3Not yet recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Sep 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 3, randomised, open-label trial of mitoxantrone hydrochloride liposome in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoints: Progression-free survival at 2 years and Overall survival at 2 years. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05717764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717764.